This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  


Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual... Read more

Blue Earth Diagnostics celebrates five year anniversary

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs... Read more

Oxford Bus Company and the Oxford Science Park form partnership as part of joint drive to improve connectivity

OXFORD BUS COMPANY AND THE OXFORD SCIENCE PARK FORM PARTNERSHIP AS PART OF JOINT DRIVE TO IMPROVE CONNECTIVITY Oxford, UK, March 5 2019 – Oxford Bus Company and The Oxford Science Park have formed a partnership to strengthen the PickMeUp on-demand minibus service in the Eastern Arc of the city. The Oxford Science Park has become a formal corporate partner of the innovative ride sharing service, providing annual investment to support... Read more

Vaccitech Awarded BARDA contract valued at $8.5M to conduct Phase II trial for Influenza Vaccine

Oxford, UK – 4 March 2019 Vaccitech announced today that it has been awarded a contract valued at $8.5 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the advanced clinical development of its recombinant Modified Vaccinia Ankara (MVA) vaccine candidate for prevention of seasonal... Read more

First production and administration of Axumin (fluciclovine (18F)) in Italy

Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.  Axumin is a novel molecular imaging agent approved in the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected... Read more

The Daubeny Project

Imaginative design, inspiring spaces.